Pyrrole-derivatives as factor Xa inhibitors

US7465806B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Armin Bauer · Pocking, DE
• Michael Wagner · Frankfurt am Main, DE
• Marc Nazare · Idstein, DE
• Volkmar Wehner · Bischofsheim a.d.Rhön, DE
• Matthias Urmann · Eschborn, DE
• Hans Matter · Langenselbold, DE

Key dates

• Filing date: Aug 25, 2006
• Grant date: Dec 16, 2008
• Expiry date: Aug 25, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formulae I and Ia,wherein R0; R1; R3; R4; R22, Q; V, G and M have the meanings indicated in the claims. The compounds of the formulae I and Ia are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ia, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.